CClinicalTrials.gg
Sign In
Not yet recruitingNCT07301437Updated Mar 23, 2026

RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

A Phase 4 interventional study of liraglutide monotherapy and liraglutide combined with orlistat in Overweight and Obese Adults, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

02

Conditions studied

  • Overweight and Obese Adults

Browse trials for

03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 850 are open to participants now.

This study's planned enrollment of 120 is above the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine is the lead sponsor of 90 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
  • Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
  • No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.

Exclusion criteria

Exclusion Criteria:

  • Allergy to liraglutide, orlistat or excipients
  • Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR \<30 mL/min
  • Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
  • Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
  • Pregnant or lactating women
  • Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    experimental group

    Drug: liraglutide combined with orlistat

  • Active comparator
    control group

    Drug: liraglutide monotherapy

Interventions

  • Drugliraglutide monotherapy

    liraglutide monotherapy

  • Drugliraglutide combined with orlistat

    combination therapy

06

What researchers measure

Primary outcomes

  1. weight loss

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07301437
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
May 1, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Mar 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Overweight→

Other studies from this sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Start the discussion